Inovio Pharmaceuticals (INO)
(Delayed Data from NSDQ)
$6.48 USD
-0.21 (-3.14%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $6.47 -0.01 (-0.15%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Balance Sheet
Fiscal Year End for Inovio Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 145 | 253 | 401 | 412 | 90 |
Receivables | 2 | 12 | 8 | 19 | 2 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 51 | 39 | 40 | 3 |
Total Current Assets | 153 | 315 | 448 | 471 | 94 |
Net Property & Equipment | 5 | 8 | 17 | 11 | 13 |
Investments & Advances | 3 | 2 | 4 | 5 | 6 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 13 | 13 | 14 | 14 |
Deposits & Other Assets | 1 | 1 | 1 | 26 | 3 |
Total Assets | 171 | 349 | 496 | 540 | 144 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 17 | 0 | 0 | 0 | 0 |
Accounts Payable | 21 | 81 | 48 | 22 | 19 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 2 | 11 | 10 | 10 | 4 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 3 | 5 | 8 | 7 |
Total Current Liabilities | 43 | 97 | 66 | 42 | 32 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 17 | 15 | 14 | 64 |
Long-Term Debt | 0 | 0 | 0 | 5 | 13 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 9 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 54 | 126 | 96 | 79 | 139 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,741 | 1,711 | 1,610 | 1,367 | 743 |
Retained Earnings | -1,623 | -1,488 | -1,210 | -906 | -740 |
Other Equity | -1 | -1 | 0 | 0 | 2 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 117 | 222 | 400 | 461 | 5 |
Total Liabilities & Shareholder's Equity | 171 | 349 | 496 | 540 | 144 |
Total Common Equity | 117 | 222 | 400 | 461 | 5 |
Shares Outstanding | 22.70 | 20.70 | 17.50 | 15.50 | 8.40 |
Book Value Per Share | 5.17 | 10.74 | 22.84 | 29.75 | 0.64 |
Fiscal Year End for Inovio Pharmaceuticals, Inc falls in the month of December.
All items in Millions except Per Share data.
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 110 | 106 | 145 | 167 | 195 |
Receivables | 2 | 3 | 2 | 2 | 5 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 4 | 5 | 5 | 3 |
Total Current Assets | 118 | 112 | 153 | 175 | 203 |
Net Property & Equipment | 5 | 5 | 5 | 6 | 6 |
Investments & Advances | 2 | 3 | 3 | 3 | 3 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 11 |
Deposits & Other Assets | 1 | 1 | 1 | 1 | 1 |
Total Assets | 134 | 129 | 171 | 193 | 233 |
Liabilities & Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 17 | 16 | 17 |
Accounts Payable | 19 | 18 | 21 | 16 | 23 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 3 | 2 | 5 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 4 | 4 |
Total Current Liabilities | 26 | 23 | 43 | 44 | 52 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 37 | 35 | 54 | 55 | 64 |
Shareholders Equity | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 1,783 | 1,749 | 1,741 | 1,737 | 1,734 |
Retained Earnings | -1,686 | -1,653 | -1,623 | -1,598 | -1,564 |
Other Equity | -1 | -1 | -1 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 97 | 94 | 117 | 138 | 169 |
Total Liabilities & Shareholder's Equity | 134 | 129 | 171 | 193 | 233 |
Total Common Equity | 97 | 94 | 117 | 138 | 169 |
Shares Outstanding | 25.90 | 23.30 | 22.70 | 22.30 | 21.80 |
Book Value Per Share | 3.74 | 4.05 | 5.17 | 6.20 | 7.77 |